Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perils with Pirfenidone and "the tuberculosis link".

Madhav H Hande1, K Vishak Acharya2, A Shreenivasa2

  • 1Department of Medicine, Kasturba Medical College, MAHE, Mangalore, Karnataka, India.

International Journal of Mycobacteriology
|September 13, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular identification of <i>Pseudodiscus collinsi</i> from wild Indian elephant (<i>Elephas maximus indicus</i>) based on ITS-2.

Helminthologia·2025
Same author

The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation.

ESMO open·2025
Same author

Jaw-Opening Myoclonus: A Rare and Distinctive Sign in Subacute Sclerosing Panencephalitis.

Annals of Indian Academy of Neurology·2025
Same author

Piezo-Assisted Transmaxillary Approach for Microscope-Enabled Debulking of Infratemporal Schwannoma.

Journal of maxillofacial and oral surgery·2025
Same author

Clinical usefulness of nebulized dexmedetomidine for conscious sedation in daycare flexible bronchoscopy in Southern India.

Indian journal of pharmacology·2024
Same author

The elusive extremities: a case of extramammary Paget disease.

BMJ case reports·2024

Patients with idiopathic pulmonary fibrosis (IPF) on pirfenidone may face an increased risk of developing tuberculosis (TB). A rare skin reaction, exfoliative dermatitis, occurred due to pirfenidone and rifampicin interaction.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Dermatology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease.
  • Pirfenidone is an antifibrotic medication used to treat IPF.
  • Tuberculosis (TB) is an infectious disease primarily affecting the lungs.

Observation:

  • A patient diagnosed with IPF and treated with pirfenidone developed TB.
  • The patient later experienced exfoliative dermatitis, a severe skin reaction.
  • This dermatitis was attributed to an interaction between pirfenidone and rifampicin, an anti-TB drug.

Findings:

  • This case suggests a potential increased risk of TB in IPF patients receiving antifibrotic therapy.
  • A previously undocumented adverse drug reaction involving pirfenidone and rifampicin was observed.
Keywords:
Idiopathic pulmonary fibrosispirfenidonerifampicintuberculosis

Related Experiment Videos

  • The interaction led to severe exfoliative dermatitis.

    • Implications:

    • Clinicians should consider the risk of TB in IPF patients on pirfenidone.
    • Awareness of this potential drug interaction is crucial for managing co-existing TB and IPF.
    • Further investigation into pirfenidone-rifampicin interactions and associated dermatological reactions is warranted.